Ignite Creation Date:
2024-05-06 @ 6:50 PM
Last Modification Date:
2024-10-26 @ 2:56 PM
Study NCT ID:
NCT05809635
Status:
RECRUITING
Last Update Posted:
2024-04-12
First Post:
2023-03-30
Brief Title:
Study of BEST1 Vitelliform Macular Dystrophy
Sponsor:
Columbia University
Organization:
Columbia University
Study Overview
Official Title:
Natural History Study in Retinitis Pigmentosa Caused by Mutations in the BEST1 Gene
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to establish the natural history of of participants with BESTROPHIN 1 Vitelliform Macular Dystrophy
The blinding disorder Best Vitelliform Macular Dystrophy VMD is caused by any one of more than 250 different mutations in the BEST1 gene
As new treatments are developed a clear understanding of the natural history of disease progression of BEST1 VMD is necessary The goals of this natural history study are to
1 Report the natural history of retinal degeneration in participants with a clinical diagnosis of VMD with molecular confirmation of a pathogenic BEST1 mutations
2 Identify sensitive structural and functional outcome measures to use for future multicenter clinical trials for the treatment of BESTROPHIN 1 VMD
3 Compare progression of the identified structural and functional measures between the two eyes to judge the suitability of the second untreated eye as a control for a future clinical trial involving unilateral treatment
4 Identify well-defined patient populations for future clinical trials of investigative treatments for BEST1 VMD
The blinding disorder Best Vitelliform Macular Dystrophy VMD is caused by any one of more than 250 different mutations in the BEST1 gene
As new treatments are developed a clear understanding of the natural history of disease progression of BEST1 VMD is necessary The goals of this natural history study are to
1 Report the natural history of retinal degeneration in participants with a clinical diagnosis of VMD with molecular confirmation of a pathogenic BEST1 mutations
2 Identify sensitive structural and functional outcome measures to use for future multicenter clinical trials for the treatment of BESTROPHIN 1 VMD
3 Compare progression of the identified structural and functional measures between the two eyes to judge the suitability of the second untreated eye as a control for a future clinical trial involving unilateral treatment
4 Identify well-defined patient populations for future clinical trials of investigative treatments for BEST1 VMD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R24EY028758 | NIH | None | httpsreporternihgovquickSearchR24EY028758 |